UA41879C2 - Засіб для лікування мотонейронових захворювань - Google Patents

Засіб для лікування мотонейронових захворювань

Info

Publication number
UA41879C2
UA41879C2 UA94085678A UA94085678A UA41879C2 UA 41879 C2 UA41879 C2 UA 41879C2 UA 94085678 A UA94085678 A UA 94085678A UA 94085678 A UA94085678 A UA 94085678A UA 41879 C2 UA41879 C2 UA 41879C2
Authority
UA
Ukraine
Prior art keywords
motoneurons
drug
treating diseases
diseases affecting
bulbar
Prior art date
Application number
UA94085678A
Other languages
English (en)
Russian (ru)
Inventor
Ерік Лювель
Эрик Лювель
Original Assignee
Рон- Пуленк Рорер С.А.
Рон-Пуленк Рорер С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9427427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA41879(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Рон- Пуленк Рорер С.А., Рон-Пуленк Рорер С.А. filed Critical Рон- Пуленк Рорер С.А.
Publication of UA41879C2 publication Critical patent/UA41879C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Винахід відноситься до застосування 2-аміно-6-трифторметокси-бензотіазолу або солі цієї сполуки з фармацевтично прийнятною кислотою для отримання лікарського засобу, призначеного для лікування мотонейронових захворювань, особливо латерального аміотрофічного склерозу і, особливо, латерального аміотрофічного склерозу з бульбарним початком або в бульбарной формі.
UA94085678A 1992-03-06 1992-10-22 Засіб для лікування мотонейронових захворювань UA41879C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9202696A FR2688138B1 (fr) 1992-03-06 1992-03-06 Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
PCT/FR1992/000992 WO1993017683A1 (fr) 1992-03-06 1992-10-22 Application de l'amino-2 trifluoromethoxy-6 benzothiazole (riluzole) pour obtenir un medicament destine au traitement des maladies du motoneurone

Publications (1)

Publication Number Publication Date
UA41879C2 true UA41879C2 (uk) 2001-10-15

Family

ID=9427427

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94085678A UA41879C2 (uk) 1992-03-06 1992-10-22 Засіб для лікування мотонейронових захворювань

Country Status (22)

Country Link
US (1) US5527814A (uk)
EP (2) EP0558861A1 (uk)
JP (1) JP2713384B2 (uk)
KR (1) KR100190296B1 (uk)
AT (1) ATE149833T1 (uk)
AU (1) AU666150B2 (uk)
CA (1) CA2117466C (uk)
CZ (1) CZ281293B6 (uk)
DE (1) DE69218255T2 (uk)
DK (1) DK0627919T3 (uk)
ES (1) ES2098558T3 (uk)
FR (1) FR2688138B1 (uk)
GR (1) GR3022797T3 (uk)
HU (1) HU217130B (uk)
IL (1) IL103493A (uk)
MX (1) MX9206109A (uk)
NO (1) NO306534B1 (uk)
RU (1) RU2110260C1 (uk)
SK (1) SK279046B6 (uk)
UA (1) UA41879C2 (uk)
WO (1) WO1993017683A1 (uk)
ZA (1) ZA928213B (uk)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
ATE200423T1 (de) * 1995-10-26 2001-04-15 Sanofi Synthelabo Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
KR20010022204A (ko) 1997-07-25 2001-03-15 닛뽄카야쿠가부시키가이샤 신경세포 분화 촉진작용을 가진 신규 화합물
CA2317811A1 (en) * 1998-01-09 1999-07-15 Mor-Research Applications Ltd. Treatment of dyskinesias
US6417210B1 (en) 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
FR2785808B1 (fr) * 1998-11-13 2002-12-06 Aventis Laboratoire Association riluzole et alpha-tocopherol
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
EP1552831B1 (en) * 1999-06-04 2009-01-07 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for treating multiple sclerosis
JP2001021609A (ja) * 1999-07-07 2001-01-26 Mitsubishi Electric Corp 半導体集積回路の検査方法
DE19940524C2 (de) * 1999-08-26 2003-06-18 Karl-Heinz Lenzkes Fahrzeugrad, insbesondere für Personenkraftfahrzeuge
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US6964982B2 (en) 2000-04-20 2005-11-15 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
WO2002034264A1 (fr) * 2000-10-24 2002-05-02 Mitsubishi Pharma Corporation Medicaments pour traiter la sclerose laterale amyotrophique (sla)
JP2004531691A (ja) * 2000-11-22 2004-10-14 アラーガン、インコーポレイテッド 一過性ナトリウムチャネルと持続性ナトリウムチャネルとを選択的に識別するチャネル遮断薬を同定するためのハイスループットスクリーン
US6479458B1 (en) 2001-11-08 2002-11-12 Allergan, Inc. Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
US7361478B2 (en) * 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
CA2468747C (en) * 2001-12-11 2011-05-31 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
DK1551793T3 (en) * 2002-06-19 2016-04-25 Gnt Pharma Co Ltd Tetrafluorobenzyl derivatives and pharmaceutical compositions containing these for the prevention and treatment of acute and chronic neurodegenerative diseases of the central nervous system
EP2526944B1 (en) * 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
CN101180263B (zh) * 2005-05-25 2011-11-02 株式会社中外制药 取代四氟苄基苯胺化合物及其药学可接受的盐的制备方法
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
US9629817B2 (en) 2005-08-25 2017-04-25 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
AU2007253899A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of R(+) and S(-) pramipexole and methods of using the same
EP2050467B1 (en) 2006-07-19 2014-09-10 Nippon Medical School Foundation Therapeutic agent for amyotrophic lateral sclerosis
JP2010504338A (ja) * 2006-09-20 2010-02-12 メディベイション ニューロロジー， インコーポレイテッド 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
RU2454409C2 (ru) 2007-03-14 2012-06-27 Нопп Ньюросайенсиз, Инк. Синтез хирально очищенных замещенных бензотиазолдиаминов
KR100852962B1 (ko) * 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
CN101983074A (zh) * 2008-04-03 2011-03-02 弗·哈夫曼-拉罗切有限公司 Peg化的igf-i变体在神经肌肉病治疗中的应用
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
EP2228055A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole liquid emulsions
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP2512514B1 (en) 2009-12-14 2014-11-05 Kyoto University Screening method for identifying compounds for treating amyotrophic lateral sclerosis
WO2012029994A1 (en) 2010-09-02 2012-03-08 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013192610A2 (en) * 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
EP2882429B1 (en) 2012-08-07 2024-04-10 The General Hospital Corporation Potassium-channel openers for use in treating amyotrophic lateral sclerosis (ALS)
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
US20150210679A1 (en) 2014-01-28 2015-07-30 Northwestern University Small molecule inhibitors of superoxide dismutase expression
EP3246046A4 (en) 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
CN111201438A (zh) 2017-06-02 2020-05-26 朱诺治疗学股份有限公司 与和细胞疗法相关的毒性有关的制品和方法
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
US10322114B2 (en) * 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
EP3676403A1 (en) 2017-09-01 2020-07-08 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN113508127A (zh) 2018-11-06 2021-10-15 阿尔萨泰克公司 神经变性疾病的基于细胞的基因疗法
FI3886894T3 (fi) 2018-11-30 2024-05-24 Juno Therapeutics Inc Menetelmiä annosteluun ja b-solumaligniteettien hoitoon adoptiivisessa soluterapiassa
PT3886875T (pt) 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
BR112022010310A2 (pt) 2019-12-06 2022-08-16 Juno Therapeutics Inc Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
FR2619713B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
DE68903484T2 (de) * 1988-12-15 1993-03-18 Rhone Poulenc Sante 2-imino-6-polyfluoralkoxy-benzothiazol-derivate, verfahren zu deren herstellung und arzneimittel, die sie enthalten.
FR2649702B1 (fr) * 1989-07-13 1991-11-22 Rhone Poulenc Sante Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2662160B1 (fr) * 1990-05-18 1992-07-24 Rhone Poulenc Sante Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
FR2663029B1 (fr) * 1990-06-07 1992-07-31 Rhone Poulenc Sante Derives de benzothiazole, leur preparation et les medicaments les contenant.

Also Published As

Publication number Publication date
DK0627919T3 (da) 1997-05-12
AU666150B2 (en) 1996-02-01
GR3022797T3 (en) 1997-06-30
DE69218255D1 (de) 1997-04-17
ATE149833T1 (de) 1997-03-15
HU9402558D0 (en) 1994-11-28
RU94041223A (ru) 1996-10-20
NO943256L (no) 1994-09-02
JPH07504655A (ja) 1995-05-25
HU217130B (hu) 1999-11-29
CZ212094A3 (en) 1994-12-15
AU2948292A (en) 1993-10-05
DE69218255T2 (de) 1997-09-11
JP2713384B2 (ja) 1998-02-16
CZ281293B6 (cs) 1996-08-14
US5527814A (en) 1996-06-18
WO1993017683A1 (fr) 1993-09-16
EP0627919B1 (fr) 1997-03-12
KR950700060A (ko) 1995-01-16
KR100190296B1 (ko) 1999-06-01
FR2688138A1 (fr) 1993-09-10
CA2117466C (fr) 2000-01-25
CA2117466A1 (fr) 1993-09-16
IL103493A0 (en) 1993-03-15
SK279046B6 (sk) 1998-06-03
ES2098558T3 (es) 1997-05-01
NO943256D0 (no) 1994-09-02
EP0558861A1 (fr) 1993-09-08
SK104794A3 (en) 1995-05-10
ZA928213B (en) 1993-04-30
FR2688138B1 (fr) 1995-05-05
MX9206109A (es) 1993-09-01
NO306534B1 (no) 1999-11-22
EP0627919A1 (fr) 1994-12-14
IL103493A (en) 1996-07-23
HUT70946A (en) 1995-11-28
RU2110260C1 (ru) 1998-05-10

Similar Documents

Publication Publication Date Title
UA41879C2 (uk) Засіб для лікування мотонейронових захворювань
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
BG101118A (en) Therapeutical compounds
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
HU9403323D0 (en) 4-mercaptioacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors
CA2289717A1 (en) Novel therapy for constipation
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
HRP930239A2 (en) Anti-inflamatory 4-aminophenol derivatives
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
ES2173858T3 (es) Analogos de huperzina a.
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
GB2380939B (en) Treatment or prevention of auto-immune diseases
ZA979647B (en) Heterocyclic compounds, compositions and uses.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
HUP9901247A3 (en) Use of naphthimidazole-, naphthoxazole- and naphthothiazole-diones for the preparation of pharmaceutical compositions treating diseases caused by vascular function deficiency
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
GR3021171T3 (en) Use of hyaluronic acid and forms to prevent arterial restenosis.
ZA929879B (en) Compositions for the treatment of mammalian diseases.
BG106151A (en) Pharmaceutical complex
ZA979650B (en) Heterocyclic compounds, compositions and uses.
ZA979645B (en) Heterocyclic compounds, compositions and uses.